Navigation Links
BioMarin to Host a Research and Development Day on December 8th
Date:11/17/2011

NOVATO, Calif., Nov. 17, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Thursday, December 8, 2011 from 8:00 a.m. to 12:00 p.m. at the Four Seasons Hotel in New York City.  Members of BioMarin's management team and industry experts will provide an update on the company's product portfolio and advancements in the research and development pipeline.Dial-in informationToll-free number: (877) 643-7155International number: (914) 495-8552Conference ID #: 28775391Replay informationToll-free number: (855) 859-2056International number: (404) 537-3406Conference ID #: 28775391Interested parties may access a live audio webcast and slides of the presentation via the investor section of the BioMarin website, http://www.BMRN.com.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA; PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU; BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease; and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Announces Third Quarter 2011 Financial Results
2. BioMarin to Present at the UBS Global Life Sciences Conference
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Baird Health Care Conference
5. BioMarin to Present at the Wedbush Life Sciences Conference
6. BioMarin Announces Second Quarter 2011 Financial Results
7. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
8. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
9. BioMarin to Present at the William Blair Growth Stock Conference
10. BioMarin to Present at the Jefferies Global Healthcare Conference
11. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... YORK, Pa. , Feb. 8, 2016  Unilife Corporation ... developer and supplier of injectable drug delivery systems, today announced ... and six months ended December 31, 2015 after market close ... not scheduled a conference call to discuss these financial results.  ... About Unilife Corporation --> About Unilife ...
(Date:2/8/2016)... 8, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced that the U.S. Food and Drug Administration ... (IND) application for SB-318, a single treatment strategy ... Type I (MPS I). The SB-318 IND application ... a Phase 1/2 clinical study (SB-318-1502) designed to ...
(Date:2/8/2016)... Feb. 8, 2016  CTI BioPharma Corp. (CTI BioPharma) ... written communication from the U.S. Food and Drug Administration ... placed a partial clinical hold on the clinical studies ... application for pacritinib. This clinical hold impacts part of ... and will also affect planned clinical trials. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert Insurance Agency, ... of a new charity campaign. As part of their ongoing community involvement program, ... the belief that children deserve a voice, and in the spirit of neighbors ...
(Date:2/8/2016)... ... February 08, 2016 , ... Brenton ... for pouches, bags, and flow wrapped products at WestPack 2015, February 9-11, in ... manufacturers step up to semi-automatic or fully-automatic case packing with a small footprint, ...
(Date:2/8/2016)... ... 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the ... has teamed up with Citizens Opposed to Domestic Abuse in support of its efforts ... all those victimized by the fear of violence in their own homes, donations may ...
(Date:2/8/2016)... ... 2016 , ... Delta Dental of California and its affiliated companies announced today ... Radine, who recently retired as president and CEO of Delta Dental of California and ... the Year , helped lead the effort to raise funds for studies to strengthen ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic stress ... women and men with eating disorders report a history of trauma, research suggests ... of an eating disorder. , At the 2016 iaedp Symposium, the workshop, ...
Breaking Medicine News(10 mins):